Kodiak Sciences (NASDAQ:KOD) Stock Price Expected to Rise, UBS Group Analyst Says

Kodiak Sciences (NASDAQ:KOD) had its price target hoisted by stock analysts at UBS Group from $120.00 to $150.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group‘s price target would indicate a potential upside of 38.92% from the company’s previous close.

A number of other equities research analysts also recently issued reports on KOD. JPMorgan Chase & Co. increased their price objective on Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. The Goldman Sachs Group assumed coverage on Kodiak Sciences in a research report on Wednesday, September 30th. They set a “neutral” rating and a $103.00 target price for the company. Lifesci Capital upped their target price on Kodiak Sciences from $85.00 to $145.00 and gave the stock an “outperform” rating in a research note on Monday, September 28th. HC Wainwright raised their price target on Kodiak Sciences from $96.00 to $126.00 and gave the company a “buy” rating in a report on Monday, October 12th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $112.00 price target on shares of Kodiak Sciences in a report on Monday, September 28th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $109.00.

Kodiak Sciences Stock Performance

NASDAQ KOD traded down $0.27 on Friday, hitting $107.98. The stock had a trading volume of 211,276 shares, compared to its average volume of 1,116,755. Kodiak Sciences has a 52-week low of $18.15 and a 52-week high of $112.31. The company has a market capitalization of $6.79 billion, a price-to-earnings ratio of -25.70 and a beta of 2.02. The firm has a 50-day moving average of $75.22 and a 200-day moving average of $45.32.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.01. As a group, research analysts anticipate that Kodiak Sciences will post -3.97 earnings per share for the current fiscal year.

Insider Transactions at Kodiak Sciences

In other news, Director Bros. Advisors Lp Baker bought 86,432 shares of the business’s stock in a transaction on Thursday, November 5th. The stock was acquired at an average price of $98.51 per share, with a total value of $8,514,416.32. Following the completion of the purchase, the director directly owned 20,424,859 shares in the company, valued at $2,012,052,860.09. This represents a 0.42% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders purchased a total of 2,188,845 shares of company stock valued at $181,326,862 over the last ninety days. 44.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Arizona State Retirement System lifted its holdings in shares of Kodiak Sciences by 6.9% in the 2nd quarter. Arizona State Retirement System now owns 8,533 shares of the company’s stock worth $332,000 after acquiring an additional 554 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Kodiak Sciences by 94.5% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,927 shares of the company’s stock valued at $73,000 after purchasing an additional 936 shares in the last quarter. KBC Group NV purchased a new stake in shares of Kodiak Sciences in the 1st quarter valued at $39,000. Sterling Capital Management LLC boosted its stake in shares of Kodiak Sciences by 850.0% in the 3rd quarter. Sterling Capital Management LLC now owns 1,311 shares of the company’s stock valued at $124,000 after purchasing an additional 1,173 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Kodiak Sciences by 15.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,468 shares of the company’s stock valued at $1,045,000 after purchasing an additional 1,509 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Kodiak Sciences

Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other eye diseases. The company’s research centers on therapies designed to address conditions involving damage to the retina and vision loss. Kodiak’s technology platform combines therapeutic antibodies with a biopolymer to create antibody biopolymer conjugates, which are designed to provide sustained treatment effects. Its development programs have included KSI-301, an investigational therapy targeting vascular endothelial growth factor (VEGF) for retinal diseases.